Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

NCT01542918 is registered in ClinicalTrials.gov with James Rubenstein as lead sponsor.

NCT NCT01542918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01542918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
Lead sponsor
James Rubenstein
Phase
Phase 1
Overall status
Completed
Start date
December 17, 2012
Completion date
August 30, 2016
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intraocular lymphoma, recurrent/refractory cns